IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignanciesPablo Domizi, Kara L. Davis, Kaithlen Zen B Pacheco et al.|Nature Communications|2025Cited by 18
IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemiaPablo Domizi, Kara L. Davis, Jolanda Sarno et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 2